PKC- as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
El-Gamal, D., Williams, K., LaFollette, T. D., Cannon, M., Blachly, J. S., Zhong, Y., Woyach, J. A., Williams, E., Awan, F. T., Jones, J., Andritsos, L., Maddocks, K., Wu, C.-H., Chen, C.-S., Lehman,Volume:
124
Language:
english
Journal:
Blood
DOI:
10.1182/blood-2014-05-574830
Date:
August, 2014
File:
PDF, 1.69 MB
english, 2014